Equities Analysts Offer Predictions for GSK Q2 Earnings

GSK PLC Sponsored ADR (NYSE:GSK) – Zacks Research boosted their Q2 2026 earnings per share (EPS) estimates for GSK in a report issued on Monday, December 1st. Zacks Research analyst Team now forecasts that the pharmaceutical company will post earnings of $1.25 per share for the quarter, up from their prior estimate of $1.22. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s Q2 2027 earnings at $1.25 EPS, Q3 2027 earnings at $1.43 EPS and FY2027 earnings at $4.86 EPS.

A number of other analysts also recently weighed in on GSK. Weiss Ratings reissued a “buy (b)” rating on shares of GSK in a report on Tuesday. Wall Street Zen upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Bank of America raised GSK from an “underperform” rating to a “neutral” rating in a research report on Tuesday, November 25th. Jefferies Financial Group reaffirmed a “buy” rating on shares of GSK in a report on Monday, October 27th. Finally, Cfra set a $53.00 price objective on GSK in a research report on Thursday, October 30th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, GSK presently has a consensus rating of “Hold” and an average price target of $44.13.

GSK Trading Down 0.4%

Shares of GSK stock opened at $48.37 on Thursday. GSK has a 1 year low of $31.72 and a 1 year high of $49.31. The company’s fifty day simple moving average is $45.78 and its 200-day simple moving average is $41.48. The company has a market cap of $98.65 billion, a price-to-earnings ratio of 13.66, a PEG ratio of 1.32 and a beta of 0.45. The company has a current ratio of 0.84, a quick ratio of 0.55 and a debt-to-equity ratio of 0.95.

GSK (NYSE:GSK) last released its earnings results on Wednesday, October 29th. The pharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.26 by $0.22. GSK had a return on equity of 48.64% and a net margin of 17.16%.The firm had revenue of $11.35 billion for the quarter, compared to analyst estimates of $8.21 billion. During the same quarter last year, the firm posted $0.50 EPS. The company’s revenue was up 6.7% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.730-4.810 EPS.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 8th. Investors of record on Friday, November 14th will be given a dividend of $0.4171 per share. This represents a $1.67 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Friday, November 14th. GSK’s dividend payout ratio (DPR) is 46.33%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of GSK. Dodge & Cox lifted its holdings in shares of GSK by 14.9% during the first quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company’s stock valued at $3,046,972,000 after acquiring an additional 10,210,921 shares during the period. Acadian Asset Management LLC lifted its holdings in GSK by 201.9% during the 1st quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company’s stock valued at $154,244,000 after purchasing an additional 2,663,270 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in GSK during the 1st quarter valued at about $67,267,000. Fisher Asset Management LLC boosted its position in GSK by 4.4% in the second quarter. Fisher Asset Management LLC now owns 31,338,405 shares of the pharmaceutical company’s stock valued at $1,203,395,000 after buying an additional 1,306,590 shares in the last quarter. Finally, Clark Capital Management Group Inc. grew its stake in GSK by 138.2% during the first quarter. Clark Capital Management Group Inc. now owns 1,565,735 shares of the pharmaceutical company’s stock worth $60,657,000 after buying an additional 908,284 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.